Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Thoracic 1Sarcoma 1Other solid neoplasm 1NET 1Head & Neck 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Breast Neoplasms 6Triple Negative Breast Neoplasms 3Neoplasm Metastasis 2Turcot syndrome 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1Stomach Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Mucopolysaccharidosis I 1Mesothelioma, Malignant 1Gastro-enteropancreatic neuroendocrine tumor 1Disease Progression 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1

Interventions

Paclitaxel 50Capecitabine 50Trastuzumab 38Fulvestrant 31pembrolizumab 27Cyclophosphamide 27Carboplatin 27Gemcitabine 23Letrozole 21palbociclib 19Docetaxel 19Lapatinib 18Bevacizumab 18exemestane 17eribulin 15Everolimus 14abemaciclib 13Vinorelbine 13Nivolumab 13Magnetic Resonance Spectroscopy 12Cisplatin 12Anastrozole 12trastuzumab deruxtecan 11Zoledronic Acid 11Doxorubicin 11Albumin-Bound Paclitaxel 11olaparib 10Tamoxifen 10Specimen Handling 10Radiotherapy 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Clinical Trials, Phase II as Topic × Breast × Clear all
NCT03475953 2023-03-03

REGOMUNE

Institut Bergonié

Phase 1/2 Unknown
747 enrolled
BreastEndocrineGastrointestinalGenitourinaryHead & NeckNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Turcot syndrome, Tertiary Lymphoid Structures, Mesothelioma, Malignant, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Triple Negative Breast Neoplasms

NCT01471847 2020-12-09

A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab

Novartis

Phase 1 Completed
5 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡